A treatment should be stopped or changed with your clinician when an adequate treatment period has not achieved its agreed goal, or when its harms and burdens outweigh the likely benefit. Serious side effects or suspected disease progression need earlier assessment, not a wait until the next scheduled review. There is no single number of days or sessions that applies to every treatment.
This is general information, not personal medical advice. Do not stop or change a prescription, transplant-related medicine, or immunosuppressive drug on your own. The examples below cover the United States and Japan; treatment decisions depend on your diagnosis, treatment plan, and local clinical guidance.

What Counts as Ineffective?
First check what the treatment was meant to do: relieve symptoms, improve function, control disease, or reduce a future risk. No visible improvement does not always mean no benefit. For example, the National Cancer Institute (NCI) explains that chemotherapy may aim to stop or slow cancer growth, reduce recurrence risk, or ease symptoms. Lack of tumor shrinkage alone therefore cannot settle every treatment decision. [1]
| Situation | What to Clarify Before Deciding |
|---|---|
| The expected response window has not passed. | Ask when this particular treatment can reasonably be assessed and which changes require an earlier review. |
| The agreed goal has not been reached at review. | Compare baseline and current results, check whether treatment was delivered as planned, and discuss stopping, adjusting, or switching. |
| Results are stable rather than better. | Ask whether stability meets the disease-control goal. Do not automatically count stability as either success or failure. |
| The hoped-for benefit was never supported for this use. | Revisit the evidence and consent discussion before committing to more sessions. |
Side effects and effectiveness are separate questions. NCI specifically cautions that chemotherapy side effects do not show how well it is fighting cancer. A treatment may still need to change because of harm, even if it has some benefit. [1]
How Long Should You Wait?
Ask for a review date and a measurable target before treatment begins, or clarify them now if they were never set. The target might be pain during a particular activity, walking ability, a laboratory result, or a scan finding. Record the starting result and use a comparable measure at follow-up.
The plan should answer four questions: What are we trying to achieve? How will we measure it? When will we review it? What happens if the target is not met? An extension should have a clinical reason and another review point, rather than an open-ended promise that the next session will work.
Blood-forming stem cell transplantation illustrates why different timelines must not be confused. NCI describes an infusion lasting about 1 to 5 hours, a treatment process taking months, and immune recovery taking several months after an autologous transplant (your own cells) or 1 to 2 years after an allogeneic transplant (donor cells) or syngeneic transplant (an identical twin’s cells). These are process and recovery timelines, not deadlines for declaring failure or stopping follow-up. An infusion already given cannot be undone by stopping later medicines. [2]
Reasons for an Earlier Review
Contact the treating team before the planned checkpoint if:
- Symptoms, scans, laboratory results, or function suggest that the disease may be progressing.
- Side effects interfere with daily life or appear to outweigh the benefit.
- The diagnosis changes, doses are missed, or there is a concern about the product, route, or treatment quality.
- An alternative becomes available that may offer a better balance of benefit and harm for your situation.
- Your priorities change, including how you weigh comfort, independence, travel, cost, and time at home.
These are reasons to reassess, not instructions to stop every treatment immediately. A new option is not automatically better for you, and a missed dose does not by itself prove treatment failure.
When Not to Wait
During cancer treatment, NCI lists possible infection signs including fever of 100.5°F (38°C) or higher, chills, cough or sore throat, catheter-site redness or swelling, and bloody or cloudy urine or pain when urinating. It advises contacting the healthcare team because infections can be life-threatening and require urgent attention. Follow your team’s own instructions and fever threshold. This is cancer-treatment guidance, not a universal cutoff for every cell-based intervention. [3]
NCI also advises speaking with the team before taking aspirin, acetaminophen, or ibuprofen for fever, because they may lower the temperature while masking a more serious problem. Do not wait for a routine effectiveness review when infection is suspected. [3]
Stopping Without Losing Care
Ask whether the next step is a supervised pause, a dose adjustment, a switch, or a move toward symptom-focused care. Before leaving, get instructions on any taper, medicines that must continue, follow-up tests, the next appointment, and whom to contact after hours.
A second opinion is easier to assess when you bring the diagnosis, prior treatments, product name, dose and route, treatment dates, baseline and follow-up results, and side-effect records. Ask the reviewing clinician what evidence would support continuing and what would justify stopping.
If treatment is part of a clinical trial, you retain the right to leave, including after signing consent. Discuss withdrawal with the study team and ask what safety follow-up is recommended and how ongoing care will be arranged; leaving a study should not mean guessing what to do with your medicines. [4]
Cell-Based Treatment Decisions
A blood stem cell transplant, an approved cell product for a specific indication, and an experimental or private-clinic cell intervention are not interchangeable. When reviewing a cell-based treatment plan in Japan, ask for the exact cell source, product, route, intended use, and regulatory status. General descriptions of regenerative medicine cannot establish that a particular intervention will help your condition.
For a study offered as evidence, check the diagnosis and disease stage, participant population, cell type, route, dose, trial phase, sample size, comparison group, measured outcomes, follow-up, and reported harms. Early trials primarily assess safety and dosing; later phases may test effectiveness against other care. A trial listing is not proof that a treatment works. [5]
The FDA warns that unapproved regenerative products have been associated with reports of blindness, tumor formation, and infection. A clinic’s offer to sell another session is not evidence of benefit. Ask what human evidence supports the proposed use and how treatment risks and complications are managed. [6]
A Product-Specific Example
In December 2024, the FDA approved Ryoncil (remestemcel-L-rknd), a donor bone marrow-derived mesenchymal stromal cell therapy, for steroid-refractory acute graft-versus-host disease in children aged 2 months and older. The supporting multicenter, single-arm study enrolled 54 children after allogeneic blood stem cell transplantation. Initial treatment was intravenous infusion twice weekly for four weeks, totaling eight infusions; participants with partial or mixed responses received additional weekly infusions for four weeks. [7]
At Day 28, 16 participants (30%) had a complete response and 22 (41%) had a partial response. These are response results at a defined time point, not cure or survival rates. The study had no comparison group, and the approval does not establish benefit for arthritis, anti-aging, or unrelated adult uses. Day 28 is not a universal stopping date for cell therapies. [7]
For Ryoncil specifically, the FDA states that the treating physician should monitor the infusion and discontinue it if there is evidence of an infusion reaction, which may include shortness of breath, low blood pressure, fever, rapid breathing, blue discoloration, or low oxygen in the blood. This is an immediate infusion-safety rule, separate from judging longer-term effectiveness. [7]
Common adverse reactions in that study included infections, fever, bleeding, swelling, abdominal pain, and high blood pressure. The FDA also identifies hypersensitivity and acute infusion reactions, infectious-agent transmission, and ectopic tissue formation as possible complications, with premedication and monitoring required. This example is not a dosing or stopping guide for other products. [7]
Japan: Filing Is Not Approval
Japan distinguishes approved regenerative medical products from services provided under the Act on the Safety of Regenerative Medicine. PMDA publishes approved-product information and review reports; check the named product and approved use rather than relying on the word “approved” in a general description. [8]
A clinic provision plan under the Act follows a separate oversight framework involving certified-committee review and submission of the plan. Filing a plan does not mean that the product has marketing approval or that its effectiveness has been established. [9] Ask for the plan or product name, the proposed use, and the explanation and consent documents. The Act’s consent provisions concern explanation and consent, not a guarantee of benefit. [10]
Make the Review Visit Useful
Bring a one-page record with the treatment goal, starting result, latest result, side effects, and the decision you need to make. Use the same activity or test for comparisons where possible. Write down the answer and the next review date before you leave.
For example, if pain on stairs was your agreed target, bring notes about that activity rather than relying only on whether you felt better on the day of the appointment. Ask the clinician to consider changes in pain medicines or activity that could affect the comparison. This is a preparation example, not a patient case or evidence that a treatment works.
- What was the treatment meant to achieve, and does the current result meet that goal?
- Has there been enough time and adequate treatment to assess it fairly?
- Does stability count as benefit in my case, or are we missing the intended target?
- What are the benefits and risks of continuing compared with changing or stopping?
- If we continue, what specific result and review date will guide the next decision?
- If we stop, which medicines, symptom treatments, tests, and follow-up must continue?
- What will another course cost, and what does that price cover?
Need help arranging a consultation about a cell-based treatment plan in Japan?
Ask about the consultation process and which records to prepare. Decisions about continuing or stopping treatment belong with the responsible clinician.
Bottom Line
Reaching a review date without the intended benefit is a reason to make a decision with your clinician, not to keep paying for open-ended treatment or to stop essential medicines alone. Confirm the goal, compare the results, weigh harms and alternatives, and leave with a clear plan. Suspected serious complications need prompt assessment, even before that review date.
References
- NCI, Chemotherapy to Treat Cancer. Accessed 13 November 2026.
- NCI, Stem Cell Transplants in Cancer Treatment. Accessed 13 November 2026.
- NCI, Infection and Neutropenia during Cancer Treatment. Accessed 13 November 2026.
- NCI, Informed Consent for Clinical Trials. Accessed 13 November 2026.
- NCI, How Clinical Trials Work. Accessed 13 November 2026.
- FDA, Important Patient and Consumer Information About Regenerative Medicine Therapies. Accessed 13 November 2026.
- FDA, Ryoncil Approval Announcement, 18 December 2024. Accessed 13 November 2026.
- PMDA, Regenerative Medical Products. Accessed 13 November 2026.
- MHLW, Regenerative and Cell Medicine and Gene Therapy. Accessed 13 November 2026.
- Japanese Law Translation, Act on the Safety of Regenerative Medicine, Article 14. Accessed 13 November 2026.




